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Introduction
Biotechnology research has much to promise human society. Beyond the
obvious benefits of being able to clone rare animal species or potentially to
revitalize extinct species1, there are many practical applications that are
beneficial to human society directly. Rare blood types might be created from
specialized stem cells. The tragedies of Christopher Reeve and others like him
who have suffered paralysis from spinal cord trauma may be reversible by using
stem cells to replenish damaged and severed nerve cells in the spinal column.2
The dire shortage of organs for those needing transplants can be reduced by
creating an organ designed specifically from the patient’s stem cells in a lab
setting to guarantee acceptance by the patient’s body.3 Israeli scientists several
years ago have already coaxed stem cells into pulsating like a heartbeat.4 The
day is very near when badly needed organs will seemingly be created from

1

If you have not already, rent Steven Spielberg’s Jurassic Park to get the idea. But for a more
mundane application go to Google.com/news and type stem cells, or go to CBSNews.com and do
a website search for stem cells. CBS has at least 20 articles written on stem cells and their
application, most of which are dated no earlier than 2000.
2
Damon J. Whitaker, Note: The Patentability of Embryonic Stem Cell Research Results, 13 J.
LAW & PUB. POL’Y 361, 365 (citing National Cancer Institute, Institutes and Centers Answers to
the Question: “What Would You Hope to Achieve From Human Pluripotent Stem Cell Research?,”
at http://222.nih.gov/news/news/stemcell/achieve.htm (Apr. 26, 2000)); see also John Bogatko,
Stem Cell Research: A Comparative Legal Analysis, 6 J. MED. & LAW 123, 126 (2002) (citing
Vanessa Lu, Spine Tissue Discovery Could Help Injury Victims; Plastic Tube Connects Tissue,
TORONTO STAR, Aug. 29, 2001, at A01; and David N. Leff, Science Scan is a ‘First’, Israelis Use
Human Embryonic Stem Cells to Create Heart-Like Beating Muscle Cells, BIOWORLD TODAY, Aug.
rd
6, 2001). On the 23 of May CBSNews.com reported that scientists were able to partially repair
damaged nerve cells in mice through stem cell injections.
3
Whitaker, supra note 2 at 365 (citing Remarks by President George W. Bush on Stem Cell
research, at http://www.whitehouse.gov/news/releases/2001/08/20010809-2.html (Aug 9, 2001)),
National Institute of Health, Stem Cells: A Primer 1, available at
http://www.nih.gov/news/stemcell/primer.htm (May 2000)).
4
Taiwo A. Oriola, Article: Ethical and Legal Issues in Singapore Biomedical Research, 11 Pac.
Rim L. & Pol’y 497, 519 (citing Tim Radford, Stem Cells Turned into Heart Tissue, GUARDIAN
UNLIMITED, Aug. 2, 2001, http:/www.guardian.co.uk/genes/article/0,2763,530902,00.html.).
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wholecloth to replace dying or diseased ones.5 Damaged skin from fires and
accidents can be replaced with skin tissue that is grown in the lab from the
patient’s own stem cells; perhaps even severely scarred tissue from fires can be
healed by injecting the damaged skin with potent stem cells. More recently, a
young boy who had the fatal Krabbe disease (a progressive and swift genetic
disorder that leads to fatal deterioration of the central nervous system)6 was
givena fighting chance of living beyond the 2 year life expectancy of those who
suffer from this disease.7 Additionally, the stem cell transplant has been so
successful that now his brain is producing 100 percent donor stem cells and his
brain should at least partially recover in four to six months.8
If the potential is so great with stem cell research, then what is all the
opposition and controversy for? There are many factors. If one thinks about how
biotechnological innovations have made what was once relegated to the creative
world of science fiction, then concern begins to mount. Simply thinking about
how the Third Reich of Nazi Germany performed horrendous scientifically based
studies on humans sends a chilling reminder of the need for ethics and morality
to step in at some point in scientific research. The question becomes however at
what point and through which mechanisms. The United States of America and

5

John Bogatko, Stem Cell Research: A Comparative Legal Analysis, 6 J. MED & LAW 123 (citing
Neil Munro, Patents, Profits, and the Stem-Cell Debate, 33 THE NAT’L J. 32 (2001); Ian Wilmut &
Lesley A. Paterson, Can it be Unethical to Heal the Sick?, THE TIMES HIGHER EDUC. SUPPLEMENT,
Aug 17, 2001, at 19; and James S. Grisoia, Stem Cell grafting for Epilepsy; Clinical Promise and
Ethical concerns, 2 EPILEPSY & BEHAV. 318, 319 (2001)); and id.
6
Eunice Kim, Tiny Struggle: Mendon Neighbors Rally to Support Toddler’s Fight for Life, METRO
W EST DAILY NEWS, May 16, 2004, available at:
http://www.metrowestdailynews.com/localRegional/view.bg?articleid=68469.
7
Id.
8
Id.
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the European Union have come up with bipolar approaches to this question and
this will be addressed below. The stem cell controversy is based on more than
the wild fantasies of science fiction writers and the horrors of cruel, vile
government experiments. The controversy enters into other moral and ethical
concerns that are more strongly grounded in our present reality.

Stem Cells: what are they, what are their benefits, what is the controversy?
A basic understanding of stem cells and ontogeny is necessary to see the
source of the ethical controversy surrounding stem cells. The human body is
composed of hundreds of millions of cells9, all derived from a single cell, that is
formed when a male’s gamete (sperm) fuses during fertilization with a female’s
gamete (egg).10 Each gamete only contains half of the necessary commands for
the assembly of a single cell; hence, the name haploid. Upon union with sperm
and egg, the newly formed diploid cell, called a zygote, undergoes a series of
divisions.11 The cell that is formed upon the union is undifferentiated and has all
the necessary commands for the 200 or so different types of cells in the human
body.12
Not all cells are alike. We have around 200 different types of cells in the
human body.13 Contrary to popular myth, most human cells do not have the

9

Whitaker, supra note 2 at 363 (citing Gerald J. Tortora & Sandra Reynolds Grabowski,
th
Principles of Anatomy and Physiology 7 (8 ed. 1996)).
10
Id. (citing id.).
11
Whitaker, supra note 2, at 364 (citing Tortora &Grabowski, supra note 6, at 80-83)
12
Meredith Mariani, Note: Stem Cell Legislation: An International and Comparative Discussion, J.
OF LEG. 379, 381 (citing House of Lords, Select Committee on Stem Cell Research Report,
Chapter 2, at http://www.publications.parliament.uk/1.htm (Feb. 13, 2002) (on file with author)).
13
Id.
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ability to divide.14 Stem cells are the cells that replace damaged or dying
specialized cells.15 Though specialized or differentiated cells perform a specific
function, they contain the exact genetic code of the original cell which was
formed when the sperm fused with egg upon fertilization. However, the
expression of certain functions is turned off and seemingly is never able to be
turned back on (at least naturally, scientists have experimented with ways to
reactivate certain functions).
During the first five days the zygote undergoes a series of critical cell
divisions.16 These cells are totipotent, meaning that they have the ability to
become any cell and to divide and specialize to become a human being. In fact,
cloning is based on taking the cells from this point in the division process. After
five days the embryo forms a blastocyst, which is the structure that is made up of
two types of cells: fetal and embryonic.17 The fetal stem cells in the outer layer of
the blastocyst are limited to becoming any type of fetal cell, while the embryo
stem cells in the inner layer of the blastocyst have the ability to become any type
of cell, except fetal cells.18 The embryonic stem cells are pluripotent, which
means that they can become any type of cell, except fetal stem cells.19 From this
point to about 14 days when the nerve streak forms the embryonic stem cells

14

Mariani, supra note 10, at 381 (citing House of Lords, Select Committee on Stem Cell
Research report, chapter 2 § 2.2, at http://www.publications.parliament01.htm (Feb. 13, 2002) (on
file with author)).
15
Id.
16
Id. at 382
17
Whitaker, supra note 2, at 364 (citing National Institute of Health, supra note 2).
18
Id.
19
Id; see also Bogatko, supra note 2 at 126-27 (citing THE NAT’L BIOETHICS ADVISORY COMM’N,
ETHICAL ISSUES IN HUMAN STEM CELL RESEARCH, VOLUME 1, REPORT AND RECOMMENDATIONS OF
THE NATIONAL BIOETHICS ADVISORY COMMISSION, at i (1999)).
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may be tapped into for their pluripotency.20 Upon the beginnings of the formation
of the nervous system, the embryonic stem cells lose their potency as they
continue to specialize and differentiate toward adult stem cells.21 Adult stem
cells are specialized stem cells that are located in bone marrow, muscle tissue,
blood, the brain, etc.22 Each type is specialized and replaces a limited type of
cells. For instance the stem cells in the muscles are limited to just replenishing
damaged or dying specialized muscle cells. Therefore, the adult stem cells are
multipotent, in that they have a multitude of cells that they can specialize into, but
they are limited to a much smaller range of cell types.23

The metaphysical debate24
The first controversy concerning stem cell research is the metaphysical
debate over when life begins. The problem with embryonic stem cell research is
that when pluripotent embryonic stem cells are removed from an embryo the
embryo is entirely destroyed. The life essence that might have been, no longer
can be. As was stated supra it is only before the blastocyst is formed that the
individual stem cells have the potential to develop into a human being. Therefore,
at that stage one could conceivably duplicate the same being. This in itself has
its own moral and ethical questions that are outside of the scope of this paper.
20

Cyril R. Vidergar, Comment: Biomedical Patenting: Permitted, but Permissible?, 19 SANTA
CLARA COMPUTER & HIGH TECH. L.J. 253, 254 (2002); and Bogatko, supra note 2, at 138.
21
See generally Bogatko, supra note 2, at 126-27; Mariani, supra note 11, at 381-85.
22
See generally Mariani, supra note 11, at 384.
23
Id.
24
For an argument engaging in the metaphysical debate to justify stem cell research see Michael
Kinsley, The False Controversy of Stem Cells: If You Think it Through, the Case for Embryonic
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However, focusing on the embryonic stem cell, we can see that once a stem cell
is pulled the entire potential for an independent life is destroyed. This brings
questions of religion, morals and ethics in
to the center of the debate.
As is evidenced by the furor and divisiveness of the abortion issue, there
has been no answer to the metaphysical debate over when human life and
human consciousness begins. As such, research on embryos, even if in their
earliest stages, is extremely controversial. In 2001, President George Bush tried
to reach a balance between two of his most powerful and active bases, the
conservative Christian Coalition and his base of doctors, scientists and
medical/pharmaceutical businesses.25 First, he allowed embryo research to
continue to be funded if they were part of a limited supply of already obtained
embryos for in vitro fertilization that were not going to be used, and hence they
would be destroyed anyway.26 Second, Bush has taken an approach similar to
the abortion issue. While the government allows abortions, states are left to
decide whether they will subsidize abortions. In this vein Bush has allowed
researchers to experiment on embryonic stem cells, but if they use embryonic
stem cells that are not part of the limited government stockpile, then they will lose
government funding.

Research is an Easy One, TIME MAGAZINE, 31 May 2004, available at:
http://www.time.com/time/magazine/article/0,9171,1101040531-641157,00.html
25
For a nice overview of these issues see Ease Stem Cell Restrictions, THE LEDGER, available at:
http://www.theledger.com/apps/pbcs.dll/article?AID=/20040508/NEWS/405080390/1036.
26
See Bogatko, supra note 2, at 142 (citing The Presidency: The Meaning of Stem Cells, TIME,
Aug 20, 2001, at 14); see also id. at 127n.25
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While this may sound like a happy compromise, it is very important to note
that the government funds 28 billion dollars a year on scientific research.27 The
threat to withdraw funding based on certain activities, is actually quite prohibitive
to researchers. And some states, realizing this, have started to consider
legislation to fund stem cell research.28 Additionally, great discoveries have been
found through privately funded research. On the other hand, perhaps these very
restrictions on embryonic stem cell prohibition will entice researches to develop
other technologies that will coax differentiated and specialized cells into
becoming undifferentiated pluripotent cells or provide incentive to seek other
potential avenues. More recently, there have been some very positive results
from adult stem cell research.29 There are currently two additional possibilities.
The first alternative is through using an unfertilized egg, gutting it out and
replacing it with the insides of any cell in the human body.30 Another option,
though only with a 1/100th success rate is to isolate cells from the human body
and put them in a supportive laboratory environment, and then starve the cell.
Typically 1/100 cells will survive, but in a less differentiated form, enabling

27

For information on a more recent bi-partisan move to increase federal funding see Stem Cell
Research: Policy and Politics, NATIONAL PUBLIC RADIO, available at:
http://www.npr.org/features/feature.php?wfId=1891207 (last visited May 25, 2004).
28
Stephanie Chavez, Stem Cell Funding is Put in the Spotlight, LOS ANGELES TIMES, available at:
http://www.latimes.com/news/local/state/la-me-nancy9may09,1,111714.story?coll=la-news-state
29
For an interesting article highlighting the dangers of embryo stem cell research and highlighting
the benefits of adult stem cell research see Wesley Smith, Adult Stem Cell Research More
Effective than Embryonic Cells, LifeNews.com, 25 May 2004, available at:
http://www.lifenews.com/bio302.html; see also Matters of Life and Death: Scientist in Stem-Cell
Cover-Up, Deliberately Exaggerate Embryonic Advances, Ignore Adult, available at:
http://worldnetdaily.com/news/article.asp?ARTICLE_ID=38633, 25 May 2004.
30
See Bogatko, supra note 2, at 128 (citing Mark Nichols, Stem Cells, A Moral Dilemma,
MACLEAN’S, Aug. 27, 2001, at 44); see also Mariani, supra note 11, at 385 (citing H.R. Rep. No.
107-170, at http://www.house.gov/judiciary/legreports.htm (July 27, 2001)).

7

scientists to use these less potent and costly cells to bypass all the ethical and
moral questions.

Stem Cells and US Patent Law.
Now that we have examined the complexity of stem cells, the
political/policy debates concerning stem cells, and covered what they are, let us
now consider stem cells and patent law in the US. The US patent system—in
fact almost any patent system--is aimed at benefiting the public. In theory,
patents work by providing the inventor an incentive to invent in the first place and
then to disclose. Disclosure to the public is rewarded by giving the inventor a
monopoly. Striking the right balance between incentive and public access
creates a tension that must be carefully balanced. A system that does not give
the inventor a long enough monopoly creates a system that lacks a strong
incentive to invent, especially in regards to things that are costly to invent. A
system that gives the inventor too long of a monopoly, burdens society, by
preventing the free market system to step in and provide a price that is in
balance with the supply and demand.
The United States has peculiar laws relative to the rest of the
industrialized world in many regards. However, as the world’s only remaining
super power and as the country with the most prolific patent system in the world
it is important in creating an international patent regime to keep in mind that
perhaps the US system is so successful because it contains some essential
traits.

8

In the US the tension between incentive for inventors and access by
society is carefully balanced by the United States Patent Act of 1952 which
stipulates four requirements for one to get a patent.31 This right to exclude is for
20 years from the date of the filing of the application. There are three types of
patents categories in the US: utility, design, and plant patents.32 There are two
dominant utility patents: process patents and product patents.33 Process patents
prevent others from using a particular process without compensation.34
However, in process patents, an inventor can create another means to reach the
same ends.35 On the other hand a product utilitypatent prevents one from using
or creating the patented product whether or not a different process was utilized.36
Typically, biotechnology inventions fall within the stipulated language of utility
patents: “whoever invents or discovers any new and useful process, machine,
manufacture, composition of matter, or any new and useful improvement thereof,
may obtain a patent therefor.”37 There are four requirements for a utility patent:

31

See generally Qin Zhang, Notes and Comments: Patent Law and Biotechnology: A Proposed
Global Solution for the Public and the Biotechnology Industry, 9 SW . J.L. & TRADE AM. 195 (200203); James J. Muchmore, Article: Proprietary Rights and the Human Genome project: A Legal
and Economic Perspective, 8 DIGEST 45 (2000); Mattias Luukkonen, Note: Gene Patents: How
Useful are the New Utility Requirements?, 23 T. JEFFERSON L. REV. 337 (2001); May Mowzoon,
Comment: Access Versus Incentive: Balancing Policies in Genetic Patents, 35 ARIZ. ST. L.J. 1077
(2003); Michael John Gulliford, Comment: Much Ado about Gene Patents: The Role of
Foreseeability, 34 SETON HALL L. REV. 711 (2004); Matthew Erramouspe, Comment: Staking
Patent Claims on the Human Blueprint: Rewards and Rent-Dissipating Races, 43 UCLA L. Rev
961 (1996); Courtney J. Miller, Comment: Patent Law and Human Genomics, 26 CAP. U.L. REV.
893 (1997); Cyril R. Videgar, Comment: Biomedical Patenting: Permitted, but Permissible?, 19
SANTA CLARA COMPUTER & HIGH TECH. L.J. 253 (2002).
32
See Erramouspe, supra note 23, at 966 (citing Thomas G. Field, Jr., Brief Survey of Intellectual
Property, 31 IDEA 85, 91-92 (1990)).
33
Id. (citing id.).
34
Id. (citing id.).
35
Id. (citing id.).
36
Id. (citing id.).
37
35 U.S.C. § 101
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utility/usefulness, novelty, non-obviousness, and disclosure.38
Under US law, “any new and useful process, machine, manufacture, or
composition of matter, or any new and useful improvement thereof” are
patentable.39 Besides usefulness, novelty is a prerequisite for a utility patent.
Before one can obtain a patent, the idea must be new. In addition, “a patent may
not be obtained…, if the differences between the subject matter sought to be
patented and the prior art are such that the subject matter as a whole would have
been obvious at the time the invention was made to a person having ordinary
skill in the [relevant] art.”40 Finally, one must make a sufficient disclosure so that
“one skilled in the art” can practice the invention
. 41
Article I, Section 8, Clause 8 of the US C
onstitution states that the
government is “to promote the Progress of Science and Useful Arts, by securing
for limited Times to Authors and Inventors the exclusive Right to their respective
Writings and Discoveries.” Congress has from time to time enacted patent
regulation to carry out this constitutional mandate. The current US patent regime
was created in 1952, well before biotechnology was even on the minds of most
congressmen. Although the US patent system does not deal with the morality of
patents, to be patent eligible the application must fall within patentable subject
matter.42
The founding fathers wanted a system that would reward creativity and

38

Id.
Id.
40
35 U.S.C. § 103
41
35 U.S.C. § 112
42
35 U.S.C. §§ 100-01
39
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invention. They realized that things would change over time; that situations
would change over time. Just as they allowed for the Constitution to be flexible
to adapt and change to unforeseen happenings and situations, so too did they
give Congress the power to create a patent system that was flexible enough to
adapt to unforeseen technologies.
Stem cells are one of many new advances in technology that our flexible
patent system has adapted to.43 The courts for a time struggled with the new
biotechnologies, seemingly wavering on incorporating the moral utility doctrine
into our system.44 Fortunately, the courts moved away from that. In the
human/animal Chimera case; the courts decided to stay away from the moral
utility doctrine and instead rejected his patent on account of the post civil war
amendments.45
Stem cells are as controversial in their own right as abortion for many of
the same reasons. Currently, the US and other industrialized nations are trying
to negotiate a world patent regime that incorporates the current universal
43

see generally Erramouspe, supra note 33, at 966-70; Gulliford, supra note 33, at 722;
Summers, supra note 33, at 484-85 &505-09; Farrell, supra note 33, at 520-530; Lacy, supra note
33, at 788-91; Videgar, supra note 33, at 256-65; Linda J. Deaine and Aaron Xavier Fellmeth,
Reinventing the Double Helix: A Novel and Nonobvious Reconceptualization of the Biotechnology
Patent, 55 STAN. L. REV. 303, 312-320; Zhang, supra note 33, at 198-202; Luukkonen, supra note
33, at 345-48; Muchmore, supra note 33, at 50-53.
44
See Benjamin D. Enerson, Note: Protecting Society From Patently Offensive Inventions: the
Risk of Reviving the Moral Utility Doctrine, 89 CORNELL L. REV. 685, 690-94) (Mr. Enerson
skillfully shows a general trend away from Justice Story’s assertion that for something to be
useful it must not be immoral and a significant move towards a patent system that does not
consider morality at all. Additionally, Mr. Enerson notes that the Revised Interim Utility Guidelines
Training Materials of the United States Patent and Trademark Office necessitates specificity,
substantiality, and credibility in utility. He notes that there is not mention concerning moral utility).
45
See Thomas A. Magnani, The Patentability of Human-Animal Chimeras, 14 BERKELEY TECH
L.J. 443, 452, 1999). In the Chimera case, though leaning towards stating that the issuance of a
patent would violate public morals, the USPTO rejected the patent application concluding that
Congress when it created the 1952 Patent Act it did “not intend to allow patents on humans or on
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application patent procedures to a substantive universal patent regime. However
there are key stumbling blocks that need to be addressed. Stem cells in
particular and biotechnology in general have thrown many challenges to our
patent system, to Europe’s patent system as well as to the patent systems of the
industrialized countries of the world.

European patent law and stem cells.
The European Union’s patent system has some starkly different rules and
regulations regarding patents. Central to these differences is the The European
Patent Convention’s (hereinafter “EPC”) statutory moral utility doctrine. On
account of the differing structures and level of use of the moral utility doctrine, the
US and EU responded differently to biotechnological innovations in general and
stem cell research in particular.46 In fact, the US system adapted more readily
and actually promoted biotechnological innovation, whereas the EU system
seemed for a time to stifle it. Even today, many in Europe wonder if they struck
the right balance via the Council Directive 98/44 on the Legal Protection of
creatures that are essentially human.” (Press Release, U.S. Patent and Trademark Office (April
1, 1998), available at http://www.upto.go/web/offices/com/s06.htm).
46
See generally Teresa M. Summers, Note: The Scope of Utility in the Twenty-First Century; New
Guidance for Gene-Related Patents, 91 GEO. L.J. 475 (2003); Enerson, supra note 47; Jasemine
Chambers, Patent Eligibility of Biotechnological Inventions in the United States, Europe and
Japan: How Much Patent Policy is Public Policy?, 34 GEO. W ASH INT’L L. REV. 223 (2002); Taiwo
A. Oriola, Article: Ethical and Legal Issues in Singapore biomedical Research, 11 PAC. RIM L. &
POL’Y 497 (2002); Timothy Caulfield, A Colloquy on the Romanow Report: Sustainability and the
Balancing of the Health Care and Innovation Agendas: The Commercialization of Genetic
Research, 66 SASK. REV. 629 (2003); Lorelei Perez Westin, Notes and Comments: Genetic
Patents: Gatekeeper to the Promised Cures, 25 T. JEFFERSON L. REV. 271 (2002); David Korn
and Stephen J. Heinig, Public Versus Private Ownership of Scientific Discovery: Legal and
Economic Analysis of the Implications of Human Gene Patents, 77.12 ACADEMIC MEDICINE 1301
(2002); and Kate Murashige, Patents and Research—An Uneasy Alliance, 77.12 ACADEMIC
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biotechnological Inventions (hereinafter “Directive 98/44/EC”), which was an
attempt to reign in the EPC’s strong codified moral utility doctrine.
The EPC provides inventors the opportunity to apply simultaneously for
patents in numerous EU countries. The EPC centralizes the application process.
However, patent infringement and enforcement challenges must be brought
within the nation in which the violation occurs.47
Article 52 of the EPC establishes four prerequisites for a patent to be
issued: 1) it must be an invention, 2) it must be novel, 3) it must have inventive
activity, and 4) it must have industrial application.48 There was controversy in the
EU over whether biotechnological innovations were patentable. Article 6 of the
EPC states that inventions must not violate ordre public or morality.49 If they do,
then citizens are given standing to show that it violates ordre public or morality
and can block the issuance of the patent.
In many EU member states, unlike the US there are laws prohibiting
certain biotech inventions from being patented.50 The US system is different
from the EU system in that the US system has classes of patents.51 While the
EU does not have classes of patents, it does preclude “the patenting of certain
biotechnological inventions.”

52

Under EPC 52 (4) gene therapy patents are

MEDICINE 1329 (1329); and David Keays, Article: Patenting DNA & Amino Acid Sequences—An
Australian Perspective, 7 HEALTH L.J. 69 (1999).
47
Enerson, supra note 44, 694 (citing Gerald Paterson, THE EUROPEAN PATENT SYSTEM: THE LAW
AND PRACTICE OF THE EUROPEAN PATENT CONVENTION SECTIONS 1-12, at 3 (2d ed. 2001)).
48
Keays, supra note 46, at 84; see generally Chambers, supra note 46.
49
Chambers, supra note 46, at 232.
50
Id.
51
Id.
52
Id.
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prohibited “because they are not susceptible to industrial application.”53
Unlike the US system, the Article 53(a) of the EPC prohibits patents for
inventions that are contrary to the morals of society. This concept is called ordre
public gives “automatic standing to concerned citizens, empowering them to
challenge individual patents on the ground that issuance would be morally
offensive and allowing the use of the judicial process to shape the law regulating
bio tech patents.54 This type of standing, ordre public, is not available in the US.
As the EU continued to fall ever further behind the US in biotechnological
innovations, Directive 98/44/EC was created “to protect inventor’s rights in
certain biotechnological produces.”55

The current international patent regime
While there are several important regional patent treaties, I wish to
address two treaties that are historical and function beyond mere regional
treaties. The first is the Paris Convention, which was signed in that late 1800s.
This treaty is designed to give national treatment to foreign inventors who are
residents of a member state. In other words, an inventor in the UK, according to
this treaty, would get the same treatment in France as a French resident. This
was a monumental step towards creating an international patent regime.
The second main international treaty (created in the mid 1990s) is the
Trade-Related Intellectual Property Rights Agreement (hereinafter “TRIPS”).

53

Id.
Id. at 233.
55
Id. at 237.
54
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TRIPS provides that patents shall be available for any inventions, whether
products or processes, in all fields of technology provided they are new, involve
an inventive step (non-obvious) and are capable of industrial application (useful).
It is important to note at the onset that TRIPS in this regard is similar to the
requirements of the EPC. Therefore, it seems that the International community is
currently following the EPC in this regard.
In addition, article 27 of TRIPS has a statutory moral utility doctrine, again
similar to the EPC over against the US patent code. Though US case law shows
a general trend towards minimizing the US common law moral utility doctrine,
cases minimizing the moral utility doctrine (such as Chakrabarty) were decided
before the passage of the TRIPS. Therefore, it remains to be seen if current US
patent case law concerning minimizing the moral utility doctrine would remain
valid in the face of the US’ ratification of TRIPS and its statutory moral utility
doctrine.
Additionally, TRIPS, again like the EPC, allows patents for inventions.
Therefore, it seems that what patent protection TRIPS does provide, resembles
the EPC over against the US patent law system. Finally, TRIPS like the EPC
provides patents for “technological innovations.” In other words, US business
methods under the EPC and under TRIPS do not seem patentable, unless they
are patents for technological innovations.
Finally, TRIPS utilizes like the EPC a patent system that has a first to file
system, while the US has a first to invent system. Therefor e, as it currently
stands, TRIPS provides a minimal substantive international patenting regime that
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is more closely aligned with the EU system, rather than the US system.

Moving towards a universal international patenting regime.56
The EU, Japan, and the US are spearheading negotiations to create a
world patent regime called the Substantive Patent Law Treaty that utilizes the
Patent Cooperation Treaty and the Patent Law Treaty. This trinity likely will one
day form a substantive world patent regime.
The first of the tripartite patent regime, the Patent Cooperation Treaty
(“PCT”) was created in 1970, amended in 1979, and modified in both 1984 and
2001.57 The treaty is open to any state part of the Paris Convention.58 It
currently is in force and has been since 1970. Article one, section one of the
PCT states that the treaty provides for “cooperation in the filing, searching and
examination, of applications for the protection of inventions, and for rendering
special technical services.” Article 1, section 2 states that “No provision of this
treaty shall be interpreted as diminishing the rights under the Paris Convention
for the Protection of Industrial Property of any national or resident of any country
party to that Convention.” In essence, the Paris Convention gave national
treatment to foreigners so long as they were residents of a state party to the
56

See id.; Shira Pridan-Frank, Article: Human-Genomics: A Challenge to the Rules of the Game
of International Law, 40 Colum. J. Transnat’l L. 619 (2002); Diana D. McCall, Note: Stating the
obvious: Patents and Biological Material, 2003 U. Ill. J.L. Tech. & Pol’y 239 (2003); James
Bradshaw, Comment: Gene Patent Policy: Does issuing Gene Patents Accord with the Purposes
of the U.S. Patent System?, 37 Willamette L. Rev 637 (2001); Trilateral Working Group:
Substantive Harmonization of Patent Law (SPLT): The European Perspective, European Patent
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Paris Convention. Therefore, the PCT clearly states that it does not add any
rights apart from those already given. In essence the PCT grants patent
applicants a streamlined process in which they can do an international patent
search for a fee. The patent search does not guarantee the granting of patents
with member states. However, it does provide an additional 18 month grace
period to the PCT patent applicant to decide whether to apply for patents around
the world.
Before moving to the second treaty in the tripartite agreement, lets first
consider how biotechnology in general and stem cells in particular would have
been dealt with at this treaty apart from the later two components. There are
two important time zones pre-TRIPS and post-TRIPS. Before the passage of
TRIPS, the Paris Convention was the key intellectual property regime and as
stated supra it invoked national treatment for applicants of member states. This
being said, stem cell research would have been accepted or denied per state
according to whether the individual state granted patents on stem cell research.
Nations at the forefront of biotechnological innovations, however, could pressure
member states through bilateral agreements or through other more aggressive
means. Pressure coming from the United States, however, is very influential and
likely to have lead to a positive result for the United States in regards to individual
bilateral agreements with nations not as willing to accept the progressive
biotechnological patenting agenda of the United States.
It seems that Article 27 of TRIPS has provided a trump card for many
58
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smaller nations with qualms about biotechnological patents: the statutory moral
utility doctrine. Furthermore, it seems that growing regional treaties such as the
European Union and the European Patent Convention have provided the many
smaller nations of Europe the bargaining power to match or even exceed that of
the United States. What this means, ultimately, is that regional agreements,
such as EPC, have provided greater, more cohesive opposition to the US
biotechnological agenda. However, this seems to have simplified things a little
bit too much, as is evidenced by EU Directive 98/44/EC, which attempted to
provide patenting protection for some biological inventions. In essence however,
it seems that pre-TRIPS the US would have had an easier time pushing its
biotechnological patent agenda, rather than in the post-TRIPS world.
Now that we have examined the first tripartite, lets take a look at the
second, the Patent Law Treaty. PLT currently is not in effect, primarily because
40, mostly unindustrialized, nations have refused to sign it. They are arguing for
implementation of the Convention on Biological Diversity.59 If enacted the treaty
would harmonize patent office formalities for the administration of patent
applications. This treaty makes clear in article three that it is nota substantive
patent law treaty, but rather that the provisions in the PLT apply to applications
that are permitted in the Paris Convention and the PCT. In other words, this
treaty creates a uniform set of rules for patent applications to all countries that
sign up. Generally speaking, this treaty neither helps nor hinders the US
biotechnological patent agenda.
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However, the third tripartite in the developing world patent regime is the
Substantive Patent Law Treaty (SPLT). If negotiations go poorly for the US, then
the US risks being excluded or having a world patent treaty that is extremely
difficult for it to accept. The main areas of concern for the United States continue
to be a statutory moral utility doctrine that preempts granting patents to any
invention that adversely affects the ordre public or morals of a society. The
United States stands to lose too much if it allows negotiations to create a world
patent regime that will not grant patents to the US’ prolific biotechnological
industries.
The United States needs to show the EU that the statutory moral utility
doctrine is very problematic. As is shown by the diversity of responses of EU
member states to biotechnology patents, EU member states that have similar
histories can not even agree on what violates the ordre public.60 This is a very
big problem. If a group of nations with shared histories cannot agree on what is
moral and what is not, then how can nations across the world? The key problem,
really, is that nations around the world do not fully realize that the United States
has mechanisms outside the patenting regime that can keep science in a comfort
zone of morality. President Bush’s response to embryonic stem cell research is
one such example. Another example involves the Chimera case, where the court
held that a patent could not be issued because it violated the post civil war
amendments.
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However, the United States may need to bend on other areas to allow for
a world patent regime that is acceptable for all nations. For instance the United
States is practically the only nation in the world that has a first to invent system.
While the rest of the world is concerned about the welfare of their societies in
general, the United States seems concerned about the welfare of individuals in
their society. The United States does this by providing a first to invent system, as
opposed to the procedurally much simpler first to file system. The rest of the
world can address the US concern of individual fairness by modifying the first to
file system by adding a comfortable grace period for inventors to claim priority
ahead of those who are first to file.
The United States needs to allow other nations to have the freedom to
prevent the utilization of biotechnology patents that they feel violate the morals of
their society. Therefore, countries like Ireland, Italy and Germany according to
such a proposition will recognize stem cell patents and other controversial
biotechnology patents, but they will have the right to exclude the utilization of that
patent within its borders. In other words, they will have the right to prevent
techniques that utilize these patents by deeming their use illegal within its
borders. This allows these more conservative countries to uphold the morals of
their society, while at the same time protecting the intellectual property of other
foreign countries.
As we examined the EPC and US patent regime we saw that the US
system was more flexible than the EPC. The US needs to argue for a patenting
the EU Directive on Biotechnology, despite pressure from member states, the United States, and
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regime that is flexible, in much the same manner as the founding fathers
establish the foundations for a flexible patenting regime. The US system
appears to have more readily responded to the challenges of biotechnology
patents. The EU system had too many hiccups and this is probably due more to
the statutory moral utility doctrine, than anything else.
As stem cells have shown us vis-à-vis patents, any successful patenting
system must be flexible and adaptable to changing and unforeseen technologies.
Without a flexible patent system that is free from the shackles of a statutory
moral utility doctrine, science and technology may be unnecessarily stunted.
That being said the response of the US system to the metaphysical debate and
the ethical considerations of stem cell research has shown that there are many
avenues outside of a patenting regime that can be used to keep science and
research within a healthy and acceptable parameter.

biotechnology industries within its borders.
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